肺结核合并肺癌患者的结核分枝杆菌耐药性分析

Drug Resistance Monitoring Analysis of Pulmonary Tuberculosis Complicated with Lung Cancer

[目的]探讨肺结核合并肺癌患者结核分枝杆菌耐药性监测情况。[方法]选取肺结核合并肺癌患者72例作为肺结核合并肺癌组，选取同期入院治疗的单纯肺结核患者94例作为肺结核组，比较两组患者结核分枝杆菌对异烟肼（INH）、利福平（RFP）、链霉素（SM）、乙胺丁醇（EMB）的耐药性情况。[结果]合并肺癌组获得性耐药为89．47％，明显高于肺结核组，差异有统计学意义（P〈0．05）；肺结核合并肺癌组耐RFP、耐EMB的几率明显高于肺结核组，差异有统计学意义（P〈0．05）；肺结核合并肺癌组耐多药几率71．93％明显高于肺结核组39．04％，差异有统计学意义（P〈0．05）。[结论]与单纯肺结核比较，肺结核合并肺癌组获得性耐药率、耐多药率较高，耐RFP、耐EMB频次增加。

[Objective]To investigate drug resistance monitoring in 72 cases of pulmonary tuberculosis complicated with lung cancer in our hospital. [Methods]Seventy-two patients with pulmonary tuberculosis complicated with lung cancer were included in the pulmonary tuberculosis with lung cancer group. Another 94 patients with simple pulmonary tuberculosis admitted in the same period were included in the pulmonary tuberculosis group. The drug resistances of Mycobacterium tuberculosis to isoniazid （INH）, rifampicin （RFP）, streptomycin （SM） and ethambutol （EMB） were analyzed. [Results]The acquired drug resistance rate of pul- monary tuberculosis with lung cancer group （89.47 %） was significantly higher than that of the pulmonary tuberculosis group （ P 〈0.05）. The probabilities of resistance to RFP and EMB in the pulmonary tuberculosis with lung cancer group were significantly higher than that in the pulmonary tuberculosis group （ P 〈0.05）. The probability of multi-drug resistance in the pulmonary tuberculosis with lung cancer group （71.93 %） was significantly higher than that in the pulmonary tuberculosis group （39.04%） （ P 〈0.05）. [Conclusion]Compared to simple pulmonary tuberculosis, the acquired drug resistance rate, multi-drug resistance rate, and frequency of resistance to RFB and EMB of pulmonary tuberculosis with lung cancer are higher.